Haleon plc (NYSE:HLN) Shares Sold by 1832 Asset Management L.P.

1832 Asset Management L.P. decreased its stake in shares of Haleon plc (NYSE:HLN) by 6.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,577 shares of the company’s stock after selling 5,933 shares during the quarter. 1832 Asset Management L.P.’s holdings in Haleon were worth $765,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Janney Montgomery Scott LLC increased its stake in shares of Haleon by 182.3% during the first quarter. Janney Montgomery Scott LLC now owns 438,833 shares of the company’s stock worth $3,726,000 after buying an additional 283,410 shares during the period. Capstone Investment Advisors LLC acquired a new position in Haleon during the 1st quarter worth approximately $1,969,000. Wellington Management Group LLP increased its position in shares of Haleon by 164.6% in the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock valued at $111,454,000 after purchasing an additional 8,423,475 shares during the last quarter. Douglas Lane & Associates LLC raised its holdings in shares of Haleon by 2.1% in the 1st quarter. Douglas Lane & Associates LLC now owns 8,401,876 shares of the company’s stock valued at $71,332,000 after purchasing an additional 175,082 shares in the last quarter. Finally, Procyon Advisors LLC lifted its position in shares of Haleon by 559.9% during the 1st quarter. Procyon Advisors LLC now owns 131,665 shares of the company’s stock worth $1,118,000 after purchasing an additional 111,713 shares during the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

HLN has been the topic of several recent analyst reports. The Goldman Sachs Group lowered Haleon from a “buy” rating to a “neutral” rating in a report on Tuesday, August 6th. Berenberg Bank started coverage on Haleon in a report on Tuesday, August 6th. They issued a “buy” rating on the stock. Finally, Morgan Stanley boosted their target price on Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.95.

Haleon Price Performance

Shares of NYSE:HLN opened at $10.59 on Friday. Haleon plc has a 12 month low of $7.70 and a 12 month high of $10.76. The firm has a market capitalization of $48.29 billion, a P/E ratio of 35.30, a P/E/G ratio of 3.12 and a beta of 0.26. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The company’s fifty day moving average price is $9.91 and its 200 day moving average price is $8.93.

Haleon (NYSE:HLN) last posted its earnings results on Thursday, August 1st. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. Haleon had a return on equity of 13.15% and a net margin of 9.71%. During the same quarter last year, the firm posted $0.08 EPS. As a group, sell-side analysts predict that Haleon plc will post 0.47 earnings per share for the current fiscal year.

Haleon Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Thursday, September 19th. Stockholders of record on Friday, August 16th were issued a $0.0514 dividend. This represents a dividend yield of 1.6%. The ex-dividend date was Friday, August 16th. Haleon’s payout ratio is currently 36.67%.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.